explore -WSS

explore

author：Wikipedia 2025-10-01 11:00:21 - browse：7439

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： New documents shed light on MD Anderson Cancer Institute feud

focus

WSS

ReNAgade cuts staff seven months after raising $300 million

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Antivenom research: Lessons from HIV applied in search for universal antidote

Pediatric cancer treatments threatened by a new FDA policy

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Cigna, Humana reportedly in talks to merge

entertainment

explore

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

At least 13 dead in Texas as scorching temps continue

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Heart attack and stroke risk calculators need revising

He's a Nobel laureate. Critics say he was misleading on Covid

Hepatitis C has a cure — but many Americans still lack access to it

6 phony surgeries that take placebo to the extreme

Medicare proposal to cover medical devices draws a mixed reaction

BIO selects John Crowley as new CEO

Peter Hotez and the public health issue of online harassment

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

knowledge

J&J to emphasize cancer drugs, stop much of its vaccine research

Community Health Systems hospitals under DOJ investigation

Antivenom research: Lessons from HIV applied in search for universal antidote

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Rep. Raul Ruiz on the physician shortage and more

In utero gene editing: an explainer

focus

focus

focus

hotspot